T-cell-Secreted TNFα Induces Emergency Myelopoiesis and Myeloid-Derived Suppressor Cell Differentiation in Cancer. 2019

Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
Tumor Immunology, Department of BioMedical Research, University of Bern, Switzerland.

Hematopoiesis in patients with cancer is characterized by reduced production of red blood cells and an increase in myelopoiesis, which contributes to the immunosuppressive environment in cancer. Some tumors produce growth factors that directly stimulate myelopoiesis such as G-CSF or GM-CSF. However, for a majority of tumors that do not directly secrete hematopoietic growth factors, the mechanisms involved in the activation of myelopoiesis are poorly characterized. In this study, we document in different murine tumor models activated hematopoiesis with increased proliferation of long-term and short-term hematopoietic stem cells and myeloid progenitor cells. As a consequence, the frequency of myeloid-derived suppressor cells and its ratio to CD8+ T cells increased in tumor-bearing mice. Activation of hematopoiesis and myeloid differentiation in tumor-bearing mice was induced by TNFα, which was mainly secreted by activated CD4+ T cells. Therefore, the activated adaptive immune system in cancer induces emergency myelopoiesis and immunosuppression. SIGNIFICANCE: These findings characterize a regulatory circuit linking activated T cells to suppression of tumor-specific immune responses, providing a conceptual advance in the understanding of emergency-hematopoiesis in cancer and opening new targets for therapeutic approaches. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/2/346/F1.large.jpg.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D001854 Bone Marrow Cells Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells. Bone Marrow Cell,Cell, Bone Marrow,Cells, Bone Marrow,Marrow Cell, Bone,Marrow Cells, Bone
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D006412 Hematopoietic Stem Cells Progenitor cells from which all blood cells derived. They are found primarily in the bone marrow and also in small numbers in the peripheral blood. Colony-Forming Units, Hematopoietic,Progenitor Cells, Hematopoietic,Stem Cells, Hematopoietic,Hematopoietic Progenitor Cells,Cell, Hematopoietic Progenitor,Cell, Hematopoietic Stem,Cells, Hematopoietic Progenitor,Cells, Hematopoietic Stem,Colony Forming Units, Hematopoietic,Colony-Forming Unit, Hematopoietic,Hematopoietic Colony-Forming Unit,Hematopoietic Colony-Forming Units,Hematopoietic Progenitor Cell,Hematopoietic Stem Cell,Progenitor Cell, Hematopoietic,Stem Cell, Hematopoietic,Unit, Hematopoietic Colony-Forming,Units, Hematopoietic Colony-Forming
D000072737 Myeloid-Derived Suppressor Cells A heterogeneous, immature population of myeloid cells that can suppress the activity of T-CELLS and NATURAL KILLER CELLS in the INNATE IMMUNE RESPONSE and ADAPTIVE IMMUNE RESPONSE. They play important roles in ONCOGENESIS; INFLAMMATION; and INFECTION. MDSC,Myeloid Derived Suppressor Cell,MDSCs,Cell, Myeloid-Derived Suppressor,Cells, Myeloid-Derived Suppressor,Myeloid Derived Suppressor Cells,Myeloid-Derived Suppressor Cell,Suppressor Cell, Myeloid-Derived,Suppressor Cells, Myeloid-Derived
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte

Related Publications

Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
October 2013, Cancer immunology research,
Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
January 2019, Cancer management and research,
Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
January 2020, Frontiers in immunology,
Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
January 2022, Frontiers in immunology,
Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
November 2021, Leukemia,
Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
February 2022, Cell death & disease,
Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
January 2024, Methods in cell biology,
Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
June 2020, Cancer immunology, immunotherapy : CII,
Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
January 2011, Trends in immunology,
Mohamad F Al Sayed, and Michael A Amrein, and Elias D Bührer, and Anne-Laure Huguenin, and Ramin Radpour, and Carsten Riether, and Adrian F Ochsenbein
November 2022, Nature communications,
Copied contents to your clipboard!